Special Issue

Inflammation-Targeted Nanomedicines for the Treatment of Chronic Inflammatory Diseases and Cancer

Message from the Guest Editors

This *Pharmaceutics* Special Issue is dedicated to exploring nanotechnology-based delivery systems targeting the inflammatory niche that characterizes chronic inflammatory diseases and cancer. Recent advances in nanomedicine have enabled the development of targeted, sustained, and responsive therapeutic platforms with the potential to overcome the limitations of conventional treatments. As , we would like to encourage colleagues to submit their research work in the format of full papers or pertinent reviews, from diverse fields such as immunology, oncology, pharmaceutical sciences, nanomedicine and regenerative medicine, to develop innovative research that advances the clinical translation of next-generation therapies for chronic inflammatory disorders and cancer. We look forward to your contributions.

Guest Editors

Dr. Rute Nunes

- 1. IUCS—Instituto Universitário de Ciências da Saúde, CESPU, Avenida Central de Gandra, 1317, 4585-116 Gandra, Portugal
- UNIPRO—Unidade de Investigação em Patologia e Reabilitação Oral, Instituto Universitário de Ciências da Saúde (IUCS-CESPU), 4585-116 Gandra, Portugal
- 3. i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal

Dr. Flávia Castro

i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/242875

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

